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Atherosclerosis is a multifactorial disease with an important inflammatory component. Inflammatory cells such as T- 
lymphocytes, macrophages and monocytes play a key role not only in its origin b u t  also during plaque rupture. In 
addition, it has been suggested that infection could be the cause of atherosclerosis. Serologic studies involving 
polymerase chain reaction, immunocytochemistry and electron microscopy support the hypothesis of an association 
between Chlamydia pneumoniae and atherosclerosis. This intracellular pathogen is able to  replicate in macrophages, 
vascular cells and smooth muscle cells. C. pneumoniae can then release inflammatory cytokines which contribute to  
instability of the plaque. C. pneumoniae may be recovered through cell culture from coronary atherosclerotic plaques 
and has a strong association with one allele, of the major histocompatibility system among patients with acute coronary 
syndromes. Other intracellular pathogens that have been implicated in atherosclerosis include cytomegalovirus. 
Mycoplasma pneumoniae and Helicobacter pylori. To test the hypothesis that C. pneumoniae plays a role in the 
instability of plaque, we conducted a prospective clinical trial, using the macrolide antibiotic roxithromycin in  202 
patients. The preliminary results show a statistically significant reduction in the incidence of acute coronary events at 
30 days. 
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The mechanisms responsible for the transition from a 
relatively stable to a clinically unstable situation in 
atherosclerotic arterial disease are still obscure. 
Activated macrophages and T-lymphocytes modify 
plaque stability through the release of cytokines, 
adhesive proteins and tissue factor [l-31. The fibrous 
layer becomes thinner and prone to rupture [4]. The 
exposure of plaque components to the bloodstream 
triggers the formation of an endoluminal thrombus and 
onset of acute coronary events [5]. During the acute 
phase of unstable angina and non-Q-wave myocardial 
infarction, the coagulation cascade is extremely active. 
Markers of fibrin production [6], such as fibrino- 
peptide A [7,8], Fragment 1+2 and the thrombin- 
antithrombin 111 complex [9] related to the amount of 
formed and circulating thrombin, indicate the activity 
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of factor Xa. O n  the other hand, d-dimer is a marker 
of fibrin degradation products plus platelet activation. 
Both of these are commonly involved in coronary 
thrombosis at the site of the mechanical plaque fissure. 
The waxing and waning of symptoms related to all of 
these components, activated either continuously or 
intermittently within the framework of unstable angina 
[10-12], justifies the widespread use of antiplatelet and 
antithrombotic drugs in the management of the acute 
coronary syndromes. 
TREATMENT OF ACUTE CORONARY SYNDROMES 
Pharmacologic studies involving antithrombotic therapy 
in patients with unstable angina have demonstrated its 
beneficial effect in this syndrome [13]. Important 
observations have supported the concept that aspirin is 
an excellent antithrombotic drug [14-161. However, 
the recurrence of ischemia in these patients was still 
very common. The introduction of unfractionated 
heparin associated with aspirin gave an additional 
benefit [ 17-19]. Unfortunately, intravenous heparin is 
associated with many problems, including the loss of 
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heparin effect and maintenance of therapeutic ranges. 
Recent studies have also demonstrated the frequency 
with which heparin falls to a subtherapeutic range, as 
reflected by activated Partial Thrombin Time (aPTT) 
In clinical practice, a substantial number of unstable 
angina patients have an adverse clinical outcome 
despite the use of aspirin and standard heparin during 
the acute phase [22]. This loss ofan initial benefit could 
be explained by the rebound activation of the 
coagulation system that follows the discontinuation of 
the heparin infusion [23,24] and the continuing 
inflammatory process that continues for up to 6 months 
from the onset of the coronary event 1251. Cyclic waves 
of thrombosis and lysis may precede clot formation, and 
lead to ischemic complications. The first efficacy 
studies conducted in arterial disease and malung use of 
a low molecular-weight heparin [26], showed its safety 
in several trials for prevention of deep vein thrombosis 
in orthopedic surgery and hemodialysis [27,28]. 
However, such studies are limited, particularly to 
the acute phase of unstable angina. A large proportion 
of patients with these acute coronary syndromes 
continue to have severe adverse outcomes despite initial 
treatment during the hospital stay. The incidence of 
death together with acute niyocardial infarction at 
hospital discharge rose to 8% by 2 months and 14% by 
1 year. Other potential pathophysiologic mechanisms 
could be implicated in the instability of the plaque. 
I13,20,21]. 
POSSIBLE ROLE OF INFECTIVE AGENTS 
Recently, there has been renewed interest in the 
possibility that coronary heart disease is associated with 
infection and specifically with Chlamydia pneumoniae 
infection. This organism is now recognized as a 
common cause of respiratory tract infection. Several 
investigators have documented an association between 
coronary heart disease and the presence of high titers 
of antibodies to C. prZeirmoniae [29-311. The organism 
has been detected in atherosclerotic plaques by use of a 
variety of techniques, including electron microscopy, 
ininiunocytochemistry and the polymerase chain 
reaction (PCR), and viable C. pneirrnoniae organisms 
have been cultured from atherosclerotic tissue 132,331. 
Furthermore, it has recently been found that C. 
yrieiAmoniue niight be involved in both atherogenesis and 
plaque instability (2,341. 
Other intracellular pathogens implicated in 
atherosclerosis include cytomegalovirus, Mycoplarma 
przeumortiue and Helicobacter pylori. However, there are 
considerable problems in investigating potential 
associations between H .  pylovi and coronary heart 
disease [35], and the impact of H.  pylori infection as an 
independent risk factor for coronary heart disease 
seems to be minor [36]. Patients with coronary heart 
disease, especially those with two- or three-vessel 
diseases, are more often H .  pylori seropositive than are 
non-diseased controls. In addition, some studies have 
demonstrated that H. pylori seropositivity is associated 
with an increase in acute myocardial infarction before 
statistical adjustment. However, after adjustment for 
these risk factors, the relation between H. pylori and 
coronary heart disease is very weak. In  addition, H. 
pylori seropositivity is inversely related to HDL 
cholesterol concentrations, but unrelated to other 
major cardiovascular risk factors 1371. 
M .  pnerirnoniae was also explored in the setting of 
acute coronary syndromes [34] but we were unable to 
find any strong correlation between this pathogen and 
symptomatic atherosclerosis. Other organisms such as 
cytomegalovirus have been associated with coronary 
artery disease, although results have been equivocal and 
the correlation between these pathogens and coronary 
artery disease is not as well established as that with 
C. prreurnoniae [38-401. 
We have investigated a possible infectious process 
associated with human leukocyte antigens (HLAs). The 
HLA system plays an iniportant role in immune 
responses to human diseases and to transplanted organs. 
We analyzed the HLA phenotypes in a sample of 
patients suffering from unstable angina, consecutively 
selected from class I and class 11. We found that among 
individual HLA DR loci, B-4 was positively related in 
patients who were seropositive for C. pneumoniae and 
who developed major ischemic complications 1411. C. 
pnenmoniae could therefore modify the immunologic 
response in this subset of patients (Figure 1). 
TREATMENT TRIAL 
We decided to test the hypothesis that treatment of 
unstable angina patients with an antibiotic with 
antichlamydial activity, such as roxithroniycin, in 
addition to conventional therapy, might reduce 
subsequent plaque instability and associated clinical 
events. The Roxis Pilot Study 1421 was a double-blind, 
randomized, prospective, multicenter, parallel group. 
placebo-controlled pilot study with a treatment phase 
of 30 days and a follow-up period of 6 months. All 
patients with non-Q-wave myocardial infarction and 
unstable angina who met criteria for type IIIb of 
Braunwald’s classification received conventional anti- 
thrombotic plus anti-ischemic therapy. When informed 
consent was obtained, patients were randomly allocated 
to receive roxithromycin 150 mg (n= 102) or its placebo 
(n=100) twice daily by mouth for 30 consecutive 
days. 
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CHRONIC INFECTION AND INMUNE 
REACTION. THE HLA SYSTEM 
HLA ANTIGENS EXPRESSED 
BACTERIAL 
PROTEINS 
Figure 1 
Chlamydia; IL, interleukin; TE tissue factor. 
Possible modlfication of immunologic responses by C. pneurnoniae. M, macrophage cell; IgG, antibody to  
Rates of recurrent ischemia of 5.4%. myocardial 6. Kruskal JB, Commerford PJ, Franks JJ, Kirsch RE. Fibrin and 
infarction of 2.2% and ischemic death of 2.2% were 
found in the placebo group, and 1.1%, 0% and 0% 
respectively in the roxithromycin group. A statistically 
significant reduction in the composite triple endpoint 
rate was observed in favor of the roxithromycin group 
(p=0.032) on intention-to-treat analysis. No sig- 
nificant drug-related adverse effects were observed. 
These results are consistent with a hypothesis of 
new mechanisms for plaque instability involving re- 
activation of chronic infection or persistent inflam- 
mation. Patients who were treated with roxithromycin 
for a period of 30 days showed a significant benefit with 
regard to major ischemic events compared to the 
control group. However, further large-scale studies are 
required to confirm these findings. 
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